查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1744544

2032 年 CT/NG 測試市場預測：按產品、測試類型、最終用戶和地區進行的全球分析

CT/NG Testing Market Forecasts to 2032 - Global Analysis By Product (Assays & Kits and Instruments/Analyzers), Testing Type (Laboratory Testing and Point-of-care (POC) Testing), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的預測，全球 CT/NG 檢測市場預計在 2025 年達到 21.6 億美元，到 2032 年將達到 43.8 億美元，預測期內的複合年成長率為 10.6%。

CT/NG檢測是指用於檢測世界上最常見的性行為感染（STI）－披衣菌感染披衣菌（CT）和淋病奈瑟菌（NG）的診斷性檢測。這些檢測對於早期診斷和治療至關重要，因為這兩種感染疾病通常無症狀，但如果不及時治療，可能會導致嚴重的健康問題，包括骨盆腔發炎和不孕症。 CT/NG檢測通常使用核酸增幅檢查（NAAT），可用於檢測尿液檢體、陰道拭子和其他檢體，具有較高的敏感性和特異性。定期篩檢是阻止這些感染疾病傳播的重要公共衛生策略，尤其是在性活躍人群中。

根據美國疾病管制與預防中心 (CDC) 的數據，2023 年美國報告了超過 240 萬例美國披衣菌感染、淋病和梅毒病例。披衣菌感染是最常見的性行為感染感染 (STI)，造成超過 160 萬例。

性傳染感染盛行率不斷上升

推動CT/NG檢測市場發展的主要因素之一是全球披衣菌感染和淋病盛行率的上升。根據美國疾病管制與預防中心（CDC）統計，光是2021年，美國就將通報超過70萬例淋病和超過160萬例披衣菌感染病例。由於無症狀性感染者往往無法確診，這些數字可能被低估。世界衛生組織（WHO）的數據顯示，全球每年新增3.74億例可治癒性感染疾病中，披衣菌感染和淋病佔了很大一部分。由於疾病負擔沉重，診斷檢測的數量急劇增加，旨在阻止疾病進一步傳播並儘早開始治療。

昂貴的高級診斷測試

儘管核酸增幅檢查(NAAT) 等先進診斷技術具有較高的靈敏度和特異性，但它們價格昂貴，可能會限制人們的獲取，尤其是在中低收入國家。資金不足的公共衛生系統和小型診所可能無法獲得這些檢測所需的昂貴試劑、專用設備和熟練的人員。這些經濟障礙阻礙了性傳染感染檢測的普及，尤其是在性傳染感染檢測資金不足的地區。此外，自付費用也可能阻礙人們定期接受檢測，尤其是對於沒有醫療保險的人口和缺乏公共醫療保健系統的地區。

遠端醫療與數位健康融合

遠端醫療平台和數位健康解決方案的日益普及，為CT/NG檢測開闢了新的途徑。人們可以透過家用檢測套組和基於應用程式的諮詢，輕鬆、謹慎地獲得性傳染感染 (STI) 服務。這些平台可以支援電子處方、遠端結果交付和樣本採集預約。數位健康工具還能實現更精準的數據收集和接觸者追蹤，從而支持公共衛生監測。此外，診斷公司擁有將檢測與數位支援服務捆綁在一起的長期機會，因為新冠疫情加速了這一趨勢，表明患者和醫療保健提供者都越來越適應並接受虛擬醫療。

在資源匱乏的環境中與綜合管理競爭

由於缺乏資金和實驗室條件，許多開發中國家仍在廣泛採用性傳染感染的綜合治療。這種方法雖然準確性較低，但透過治療症狀而無需進行確認性檢測，減少了診斷的必要性。繼續採用綜合治療會危及擴大性傳染感染/鼻咽癌檢測的能力，尤其是在成本敏感的公共衛生系統中。此外，在最需要診斷的高負擔國家，除非就地檢驗變得更容易獲得併納入現有程序，否則診斷的採用率可能仍然有限。

COVID-19的影響：

COVID-19 疫情以多種方式影響了 CT/NG 檢測市場。最初，由於供應鏈中斷、醫療系統負擔過重以及檢測資源被重新分配給 SARS-CoV-2 診斷，檢測服務受到干擾。在許多地區，針對淋病和披衣菌感染等性傳染感染的常規篩檢項目被取消或縮減，導致檢測量暫時下降，診斷延誤。然而，疫情加速了照護現場診斷、遠端醫療和自採集試劑套件的普及，為更便利、更分散的性傳染感染檢測奠定了基礎。

預計在預測期內，檢測和套件部分將成為最大的部分。

預計在預測期內，檢測和套件領域將佔據最大的市場佔有率。這種主導地位得益於核酸增幅檢查(NAAT) 等分子診斷檢測的廣泛應用，這些檢測對識別 CT/NG 感染具有高度的敏感性和特異性。這些檢測方法因其易於使用、週轉時間短且適用於自動化平台，常用於臨床實驗室、醫院，甚至是家用檢測套組。此外，由於對早期準確診斷的需求日益成長，尤其是對於無症狀性患者，基於檢測的解決方案也越來越受歡迎。因此，該細分市場目前佔據了市場收益的最大佔有率。

預計居家照護領域在預測期內將以最高複合年成長率成長

預計居家照護領域將在預測期內呈現最高成長率。這一成長的主要驅動力是對可近性、便利性和私密性性傳染感染篩檢日益成長的需求。遠距遠端醫療診斷服務和家用樣本採集試劑套件越來越受歡迎，尤其是在新冠疫情改變了患者偏好之後。這些解決方案能夠將樣本送至認證實驗室或無需前往醫療機構即可進行自我檢測，從而提高了檢測頻率並減少了污名化。此外，自我檢測的易用性、日益增強的認知度以及技術發展預計將顯著推動該市場的成長。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大市場佔有率，這主要得益於該地區龐大的人口規模、不斷上升的性傳染感染率以及日益增強的性健康意識。此外，該地區市場主導地位的很大一部分原因在於中國、印度、日本和澳洲等國家日益普及的先進診斷技術、不斷擴展的醫療基礎設施以及政府舉措性傳染感染篩檢計畫的支持。由於就地檢驗套件和核酸增幅檢查(NAAT) 的使用日益增多，亞太地區市場正在不斷擴張，使其成為全球最主要的CT/NG檢測地區。

複合年成長率最高的地區：

預計北美地區在預測期內的複合年成長率最高。這得益於其強大的醫療保健體系、對性傳染病的深入了解以及尖端診斷工具的廣泛應用。完善的報銷政策、日益增多的篩檢舉措以及持續的研發投入，共同促進了市場的擴張。此外，靈敏快速的檢測技術的普及，以及公共和私人部門對性健康計畫的投資不斷增加，也是支撐北美CT/NG檢測市場強勁成長的部分因素。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球CT/NG 檢測市場（按產品）

  • 檢測方法和套件
  • 儀器/分析儀

6.全球CT/NG 檢查市場（按檢查類型）

  • 實驗室測試
    • 核酸增幅檢查（NAAT）
    • 免疫檢測
    • 文化測試
  • 照護現場檢驗 (POC)
    • 快速診斷測試（RDT）
    • 自檢檢測套組

第7章全球 CT/NG 檢查市場（按最終用戶）

  • 診斷實驗室
  • 醫院和診所
  • 居家照護環境
  • 其他最終用戶

8.全球CT/NG檢查市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司概況

  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Binx Health, Inc.
  • Abbott Laboratories
  • Hologic Inc.
  • Siemens Healthineers AG
  • ELITech Group SAS
  • Danaher Corporation
  • Seegene, Inc.
  • Genetic Signatures Ltd.
  • Becton, Dickinson and Company（BD）
  • Qiagen NV
  • Meridian Bioscience Inc.
  • PerkinElmer Inc.
Product Code: SMRC29592

According to Stratistics MRC, the Global CT/NG Testing Market is accounted for $2.16 billion in 2025 and is expected to reach $4.38 billion by 2032 growing at a CAGR of 10.6% during the forecast period. CT/NG testing refers to diagnostic tests used to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two of the most common sexually transmitted infections (STIs) worldwide. These tests are essential for early diagnosis and treatment because, although both infections frequently show no symptoms, if treatment is not received, they can cause major health problems like pelvic inflammatory disease and infertility. Typically, CT/NG testing uses nucleic acid amplification tests (NAATs), which can be carried out with urine samples, vaginal swabs, or other specimen types and have high sensitivity and specificity. Regular screening is a crucial public health tactic to stop the spread of these infections, particularly among sexually active people.

According to the Centers for Disease Control and Prevention (CDC), over 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023. Chlamydia accounted for more than 1.6 million cases, making it the most commonly reported sexually transmitted infection (STI).

Market Dynamics:

Driver:

Growing STI prevalence

One of the major factors propelling the CT/NG testing market is the rising global incidence of chlamydia and gonorrhea. Over 700,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the United States in 2021 alone, according to the CDC. Because asymptomatic infections often go undiagnosed, these figures are probably underestimates. According to the World Health Organization (WHO), Chlamydia and gonorrhea account for a significant portion of the 374 million new curable STI infections that occur worldwide each year. In order to stop the disease from spreading further and to start treatment as soon as possible, diagnostic testing has increased dramatically as a result of this high disease burden.

Restraint:

Expensive advanced diagnostic testing

The high cost of advanced diagnostic technologies, like nucleic acid amplification tests (NAATs), can restrict access, particularly in low- and middle-income nations, despite their high sensitivity and specificity. Underfunded public health systems or smaller clinics may not be able to afford the costly reagents, specialized equipment, and skilled personnel needed for these tests. Widespread adoption is hampered by this financial obstacle, especially in places where STI testing funding is scarce. Moreover, the out-of-pocket expenses can also discourage people from getting tested on a regular basis, especially for populations without insurance or in areas without public healthcare systems.

Opportunity:

Integration of telemedicine and digital health

The increasing use of telemedicine platforms and digital health solutions is opening up new avenues for CT/NG testing. People can easily and discreetly access STI services with at-home testing kits and app-based consultations. These platforms can support electronic prescriptions for treatment, remote result delivery, and instructions for sample collection. Better data collection and contact tracing are also made possible by digital health tools, which support public health surveillance. Additionally, diagnostic companies have a long-term opportunity to bundle testing with digital support services, as the COVID-19 pandemic has accelerated this trend and demonstrated that both patients and providers are growing more at ease with virtual care.

Threat:

Competition in low-resource environments from syndromic management

Due to a lack of funding and access to laboratory testing, syndromic management of STIs is still widely used in many developing nations. This method reduces the need for diagnostics by treating symptoms without the need for confirmatory testing, despite being less accurate. The continued use of syndromic management jeopardizes CT/NG testing's ability to expand, particularly in public health systems where cost is a key consideration. Furthermore, diagnostic adoption may remain restricted in high-burden nations where it is most needed unless point-of-care tests become more accessible and incorporated into current procedures.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the CT/NG testing market. At first, it caused testing services to be disrupted because of supply chain disruptions, the overburden on the healthcare system, and the reallocation of laboratory resources to SARS-CoV-2 diagnostics. As a result of the suspension or reduction of routine screening programs for STIs, such as gonorrhea and chlamydia, in many areas, testing volumes temporarily decreased and diagnoses were delayed. The pandemic did, however, also hasten the uptake of point-of-care diagnostics, telemedicine, and self-collection kits, establishing the foundation for more accessible and decentralized STI testing.

The assays & kits segment is expected to be the largest during the forecast period

The assays & kits segment is expected to account for the largest market share during the forecast period. The extensive use of molecular diagnostic tests, like nucleic acid amplification tests (NAATs), which are very sensitive and specific for identifying CT/NG infections, is what is causing this dominance. Because of their simplicity of use, quick turnaround times, and compatibility with automated platforms, these assays are frequently utilized in clinical laboratories, hospitals, and even at-home testing kits. Moreover, assay-based solutions have become increasingly popular due to the increasing need for early and precise diagnosis, particularly in asymptomatic individuals. As a result, this market segment now accounts for the largest portion of market revenue.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate. The primary drivers of this growth are the growing demands for STI screening that are accessible, convenient, and private. Telehealth-based diagnostic services and at-home sample collection kits have become increasingly popular, especially since the COVID-19 pandemic changed patient preferences. By enabling people to send samples to accredited labs and perform self-tests without having to visit medical facilities, these solutions improve testing frequency and lessen stigma. Additionally, self-testing's ease of use, growing awareness, and technological developments are anticipated to greatly speed up this market's growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, mainly due to the region's population size, rising STI rates, and growing sexual health consciousness. Furthermore, the region's market dominance is largely due to growing access to advanced diagnostic technologies in nations like China, India, Japan, and Australia, as well as expanding healthcare infrastructure and government initiatives supporting STI screening programs. The market in Asia-Pacific is expanding due to the growing use of point-of-care testing kits and nucleic acid amplification tests (NAATs), which has made the region the world's most prominent location for CT/NG testing.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, motivated by a robust healthcare system, a high level of knowledge about STDs, and the broad use of cutting-edge diagnostic tools. Strong reimbursement practices, expanding screening initiatives and continuous R&D efforts all contribute to the market's expansion. Additionally, variables supporting the strong growth of the CT/NG testing market in North America include the availability of highly sensitive and quick testing techniques, as well as rising public and private investments in sexual health programs.

Key players in the market

Some of the key players in CT/NG Testing Market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Binx Health, Inc., Abbott Laboratories, Hologic Inc., Siemens Healthineers AG, ELITech Group SAS, Danaher Corporation, Seegene, Inc., Genetic Signatures Ltd., Becton, Dickinson and Company (BD), Qiagen N.V., Meridian Bioscience Inc. and PerkinElmer Inc.

Key Developments:

In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad's StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments. The new two-kit system provides researchers access to Bio-Rad's StarBright Blue and StarBright Violet Dyes, employing Bio-Rad's SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice.

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

Products Covered:

  • Assays & Kits
  • Instruments/Analyzers

Testing Types Covered:

  • Laboratory Testing
  • Point-of-care (POC) Testing

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global CT/NG Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Assays & Kits
  • 5.3 Instruments/Analyzers

6 Global CT/NG Testing Market, By Testing Type

  • 6.1 Introduction
  • 6.2 Laboratory Testing
    • 6.2.1 Nucleic Acid Amplification Tests (NAAT)
    • 6.2.2 Immunoassays
    • 6.2.3 Culture Tests
  • 6.3 Point-of-care (POC) Testing
    • 6.3.1 Rapid Diagnostic Tests (RDT)
    • 6.3.2 Self-Testing Kits

7 Global CT/NG Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Home Care Settings
  • 7.5 Other End Users

8 Global CT/NG Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Bio-Rad Laboratories, Inc.
  • 10.2 F. Hoffmann-La Roche Ltd.
  • 10.3 Thermo Fisher Scientific, Inc.
  • 10.4 Binx Health, Inc.
  • 10.5 Abbott Laboratories
  • 10.6 Hologic Inc.
  • 10.7 Siemens Healthineers AG
  • 10.8 ELITech Group SAS
  • 10.9 Danaher Corporation
  • 10.10 Seegene, Inc.
  • 10.11 Genetic Signatures Ltd.
  • 10.12 Becton, Dickinson and Company (BD)
  • 10.13 Qiagen N.V.
  • 10.14 Meridian Bioscience Inc.
  • 10.15 PerkinElmer Inc.

List of Tables

  • Table 1 Global CT/NG Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 4 Global CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 5 Global CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 6 Global CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 7 Global CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 8 Global CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 9 Global CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 10 Global CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 11 Global CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 12 Global CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 13 Global CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 14 Global CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 15 Global CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 16 Global CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 17 Global CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 18 North America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 19 North America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 20 North America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 21 North America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 22 North America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 23 North America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 24 North America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 25 North America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 26 North America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 27 North America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 28 North America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 29 North America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 30 North America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 North America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 32 North America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 North America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 34 North America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 35 Europe CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 36 Europe CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 37 Europe CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 38 Europe CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 39 Europe CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 40 Europe CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 41 Europe CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 42 Europe CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 43 Europe CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 44 Europe CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 45 Europe CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 46 Europe CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 47 Europe CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 48 Europe CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 49 Europe CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 50 Europe CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 51 Europe CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 52 Asia Pacific CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 53 Asia Pacific CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 54 Asia Pacific CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 55 Asia Pacific CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 56 Asia Pacific CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 57 Asia Pacific CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 58 Asia Pacific CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 59 Asia Pacific CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 60 Asia Pacific CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 61 Asia Pacific CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 62 Asia Pacific CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 63 Asia Pacific CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 64 Asia Pacific CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 65 Asia Pacific CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 66 Asia Pacific CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 67 Asia Pacific CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 68 Asia Pacific CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 69 South America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 70 South America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 71 South America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 72 South America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 73 South America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 74 South America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 75 South America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 76 South America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 77 South America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 78 South America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 79 South America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 80 South America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 81 South America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 82 South America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 83 South America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 84 South America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 85 South America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 86 Middle East & Africa CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 87 Middle East & Africa CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 88 Middle East & Africa CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 89 Middle East & Africa CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 90 Middle East & Africa CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 91 Middle East & Africa CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 92 Middle East & Africa CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 93 Middle East & Africa CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 94 Middle East & Africa CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 95 Middle East & Africa CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 96 Middle East & Africa CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 97 Middle East & Africa CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 98 Middle East & Africa CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 99 Middle East & Africa CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 100 Middle East & Africa CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 101 Middle East & Africa CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 102 Middle East & Africa CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)